AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M

AtriCure, Inc.

2023-FY EPS reported -$0.66 revenue$399,245,000

Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).
Full-year 2023 net loss improved $16M to $30.4M; adjusted EBITDA turned positive to $19.4M from -$2.2M.
Full-year diluted net loss per share $0.66 vs $1.02 in 2022; adjusted loss per share $0.75 vs $1.02.
2024 revenue guidance $459-$466M (15-17% growth); adjusted EBITDA $26-$29M (34-49% increase).
Over one million patients treated life to date; management cites broad-based expansion and momentum.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

AtriCure, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2023.

Period: the fourth quarter and full-year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 15, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001323885-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.